Physician profile
Roy Marcus
NPI 1245278084
$1,676.59
in general payments reported to CMS, 2019-2025
18 companies · $207 in 2025
The $207 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $763 · 2020: $120 · 2021: $47.95 · 2022: $299 · 2024: $240 · 2025: $207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $447.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $446.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $315.12 | 2019-2025 | Aranesp, Krystexxa |
| Vifor Pharma, INC. | $274.00 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $207.07 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $173.02 | 2019-2022 | |
| Astrazeneca Uk Limited | $134.91 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $131.91 | 2022-2024 | |
| Calliditas Therapeutics US INC. | $116.11 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $83.17 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $61.23 | 2019-2025 | |
| Opko Pharmaceuticals, LLC | $52.14 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $37.82 | 2019-2020 | |
| Daiichi Sankyo INC. | $20.46 | 2019 | |
| Janssen Pharmaceuticals, INC | $20.36 | 2019 | |
| Akcea Therapeutics, INC. | $20.10 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $17.70 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $11.47 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Marcus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.